BLT 0.00% 2.6¢ benitec biopharma limited

media coverage, page-28

  1. 908 Posts.
    lightbulb Created with Sketch. 85
    This is what’s important

    From announcement


    Benitec possesses and retains rights to all human therapeutic applications of its ddRNAi technology

    and is actively exploring licensing opportunities.
 
watchlist Created with Sketch. Add BLT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.